Cell therapy that targets cancer by your tumor’s markers
Part of Cancer clinical trials.
This early-phase study tests an immune cell treatment made to attack specific “tumor markers” found in your cancer tissue. If your tumor tests positive for one or more of these markers, the trial may offer a new way to help your immune system fight a high-risk stage of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can sign informed consent before any study procedures.
- Your tumor tissue must test positive for at least one targeted cancer marker (like GD2, mesothelin, P16, or several others).
- Your cancer must be high-risk, stage III–IV (FIGO stage III-IV).
- You must have enough blood counts, kidney, and liver function to safely receive treatment.
- You must not be pregnant or breastfeeding, and must use effective birth control if you could become pregnant.
- You must not have had other cell therapy or another investigational drug recently, and you must be well enough to follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests an immune-based treatment for advanced (Stage III–IV) GI cancer. You may be able to join only if your tumor shows certain “marker” proteins on special lab staining, and your blood and organ tests meet study limits.
This Phase 1 study tests CAR-T cells that are engineered to recognize several cancer “markers” (specific proteins) found on some advanced cancers. It may help by directing the patient’s own immune cells to attack cancer, but eligibility depends on matching the required protein markers.
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
This early-phase study tests personalized immune cells (T cells) made from your own tumor and blood to treat advanced solid cancers. It may help your immune system recognize and attack your tumor, especially if standard treatments no longer work.
This trial tests a new type of immune cell therapy made from your own cells (gamma-delta T cells) that are engineered to find and attack cancers that have GPC3 or mesothelin proteins. It may be an option for people with advanced cancer who have not had gene therapy before and are in generally good health.
This trial tests a new immune cell therapy for people with advanced solid tumors of the lung, liver, colon, rectum, or breast. It aims to see if the treatment is safe and can help shrink or control the cancer.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.